Mentioned as a potential partner for Google's new eyewear hardware, leveraging the $250 billion prescription market.

The stock's recent 24% jump is considered a 'ridiculous' overreaction driven by AI hype, and the gains may not be sustainable as the partnership news is not new.

Partnering with Google to improve the design and appeal of Google's upcoming AI-enabled smart glasses.

Received a strong, albeit anecdotal, endorsement for its brand and business model, suggesting it has built a loyal customer base by offering a quality product at a competitive price.

Benefits from the authenticity and impact of host-read ads on podcasts, which effectively reach a high-spending demographic.

Mentioned in a sponsorship message for its glasses and stores; the text notes this was an advertisement and contained no investment analysis.

Mentioned as a public holding in Thrive Capital's concentrated portfolio of what it considers 'best-in-class' companies.

Used as an example of why valuation matters. An investor passed on a late-stage private round due to a 'crazy' high valuation, which proved correct as those investors likely made little to no money after the company went public.